NASDAQ:BEAM Beam Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Beam Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $40.42 +0.02 (+0.05%) (As of 06/29/2022 12:00 AM ET) Add Compare Share Today's Range$38.72▼$41.2050-Day Range$29.86▼$44.2352-Week Range$27.77▼$138.52Volume1.26 million shsAverage Volume1.19 million shsMarket Capitalization$2.84 billionP/E RatioN/ADividend YieldN/APrice Target$110.86 ProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive BEAM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Beam Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BEAM Stock Forecast (MarketRank)Overall MarketRank™1.86 out of 5 starsMedical Sector732nd out of 1,432 stocksBiological Products, Except Diagnostic Industry116th out of 217 stocksAnalyst Opinion: 3.4Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 - 3.4 Analyst's Opinion Consensus RatingBeam Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $110.86, Beam Therapeutics has a forecasted upside of 174.3% from its current price of $40.42.Amount of Analyst CoverageBeam Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 3.5 Community Rank Outperform VotesBeam Therapeutics has received 20 “outperform” votes. (Add your “outperform” vote.)Underperform VotesBeam Therapeutics has received 19 “underperform” votes. (Add your “underperform” vote.)Community SentimentBeam Therapeutics has received 51.28% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Beam Therapeutics and other stocks. Vote “Outperform” if you believe BEAM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BEAM will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldBeam Therapeutics does not currently pay a dividend.Dividend GrowthBeam Therapeutics does not have a long track record of dividend growth. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Beam Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,706,284.00 in company stock.Percentage Held by InsidersOnly 4.00% of the stock of Beam Therapeutics is held by insiders.Percentage Held by Institutions68.80% of the stock of Beam Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Beam Therapeutics are expected to decrease in the coming year, from ($4.26) to ($4.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Beam Therapeutics is -11.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Beam Therapeutics is -11.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBeam Therapeutics has a P/B Ratio of 3.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Beam Therapeutics (NASDAQ:BEAM)Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.Read More BEAM Stock News HeadlinesJune 30, 2022 | nz.finance.yahoo.comIBA signs contract with Istituto Clinico Humanitas for a Proteus®ONE proton therapy solution in ItalyJune 28, 2022 | msn.comScottie Beam Gets Candid About Music, Career & The Importance Of Self CareJune 24, 2022 | finance.yahoo.comHow Much Of Beam Therapeutics Inc. (NASDAQ:BEAM) Do Institutions Own?June 23, 2022 | finance.yahoo.comTELA Bio, Inc. (TELA) Stock Jumps 6.6%: Will It Continue to Soar?June 22, 2022 | msn.comThe Beams: Printworks co-founder Simeon Aldred on London’s new cultural powerhouseJune 21, 2022 | forbes.comAttention Leaders: Turn On Your High BeamsJune 19, 2022 | americanbankingnews.comBeam Therapeutics (NASDAQ:BEAM) Shares Up 10.5%June 19, 2022 | americanbankingnews.comBrokerages Set Beam Therapeutics Inc. (NASDAQ:BEAM) PT at $122.50June 18, 2022 | americanbankingnews.comDenali Therapeutics (NASDAQ:DNLI) & Beam Therapeutics (NASDAQ:BEAM) Financial ComparisonJune 17, 2022 | americanbankingnews.comBMO Capital Markets Begins Coverage on Beam Therapeutics (NASDAQ:BEAM)June 15, 2022 | marketwatch.comFocused Ion Beam (FIB) Market Application, Price, Demand Analysis and Growth Opportunities to 2026June 15, 2022 | nz.finance.yahoo.comBeam Dental Expands Benefits Portfolio, Rebrands to Beam BenefitsJune 14, 2022 | usnews.comFuneral Set for Las Vegas Policeman Killed by a Falling BeamSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BEAM CUSIPN/A CIK1745999 Webwww.beamtx.com Phone857-327-8775FaxN/AEmployees341Year FoundedN/ACompany Calendar Last Earnings5/09/2022Today6/30/2022Next Earnings (Estimated)8/09/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$110.86 High Stock Price Forecast$152.00 Low Stock Price Forecast$41.00 Forecasted Upside/Downside+174.3%Consensus RatingModerate Buy Rating Score (0-4)2.71428571428571 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($3.610010) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-370.64 million Net Margins-395.37% Pretax Margin-395.37% Return on Equity-28.02% Return on Assets-17.21% Debt Debt-to-Equity RatioN/A Current Ratio5.66 Quick Ratio5.66 Sales & Book Value Annual Sales$51.84 million Price / Sales54.79 Cash FlowN/A Price / Cash FlowN/A Book Value$12.13 per share Price / Book3.33Miscellaneous Outstanding Shares70,267,000Free Float67,456,000Market Cap$2.84 billion OptionableNot Optionable Beta1.61 Beam Therapeutics Frequently Asked Questions Should I buy or sell Beam Therapeutics stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Beam Therapeutics in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" Beam Therapeutics stock. View analyst ratings for Beam Therapeutics or view top-rated stocks. What is Beam Therapeutics' stock price forecast for 2022? 7 brokerages have issued 1 year price targets for Beam Therapeutics' stock. Their BEAM stock forecasts range from $41.00 to $152.00. On average, they expect Beam Therapeutics' share price to reach $110.86 in the next twelve months. This suggests a possible upside of 174.3% from the stock's current price. View analysts' price targets for Beam Therapeutics or view top-rated stocks among Wall Street analysts. How has Beam Therapeutics' stock price performed in 2022? Beam Therapeutics' stock was trading at $79.69 at the beginning of the year. Since then, BEAM stock has decreased by 49.3% and is now trading at $40.42. View the best growth stocks for 2022 here. When is Beam Therapeutics' next earnings date? Beam Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022. View our earnings forecast for Beam Therapeutics. How were Beam Therapeutics' earnings last quarter? Beam Therapeutics Inc. (NASDAQ:BEAM) announced its quarterly earnings results on Monday, May, 9th. The company reported ($1.01) EPS for the quarter, beating analysts' consensus estimates of ($1.10) by $0.09. The company earned $8.40 million during the quarter, compared to analyst estimates of $44.15 million. Beam Therapeutics had a negative net margin of 395.37% and a negative trailing twelve-month return on equity of 28.02%. The company's revenue was up 139900.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($3.35) EPS. View Beam Therapeutics' earnings history. Who are Beam Therapeutics' key executives? Beam Therapeutics' management team includes the following people: Mr. John M. Evans M.B.A., CEO & Director (Age 44, Pay $1.02M) (LinkedIn Profile)Dr. Giuseppe Ciaramella Ph.D., Pres & Chief Scientific Officer (Age 53, Pay $890.79k) (LinkedIn Profile)Ms. Terry-Ann Burrell M.B.A., CFO & Treasurer (Age 45, Pay $687.52k) (LinkedIn Profile)Dr. Feng Zhang Ph.D., Co-FounderDr. David R. Liu Ph.D., Co-FounderDr. J. Keith Joung M.D., Ph.D., Co-FounderDr. Nicole Gaudelli Ph.D., Co-FounderDr. Alexis Komor Ph.D., Co-FounderMs. Suzanne Fleming, Chief Accounting Officer (Age 61)Mr. Brian Riley, Sr. VP of Technical Operations (Age 45) What is 's approval rating as Beam Therapeutics' CEO? 1 employees have rated Beam Therapeutics CEO on Glassdoor.com. has an approval rating of 100% among Beam Therapeutics' employees. This puts in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are some of Beam Therapeutics' key competitors? Some companies that are related to Beam Therapeutics include Qiagen (QGEN), Qiagen (QGEN), Neurocrine Biosciences (NBIX), Repligen (RGEN), Exelixis (EXEL), Halozyme Therapeutics (HALO), CRISPR Therapeutics (CRSP), Ginkgo Bioworks (DNA), Novavax (NVAX), Ablynx (ABLYF), Denali Therapeutics (DNLI), Vir Biotechnology (VIR), Abcam (ABCM), Fate Therapeutics (FATE) and Bavarian Nordic A/S (BVNRY). View all of BEAM's competitors. What other stocks do shareholders of Beam Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Beam Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Editas Medicine (EDIT), Cisco Systems (CSCO), Square (SQ), Skyworks Solutions (SWKS), Akoustis Technologies (AKTS), Invitae (NVTA), QUALCOMM (QCOM) and Alector (ALEC). When did Beam Therapeutics IPO? (BEAM) raised $101 million in an initial public offering (IPO) on Thursday, February 6th 2020. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and Barclays served as the underwriters for the IPO and Wedbush PacGrow was co-manager. What is Beam Therapeutics' stock symbol? Beam Therapeutics trades on the NASDAQ under the ticker symbol "BEAM." How do I buy shares of Beam Therapeutics? Shares of BEAM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Beam Therapeutics' stock price today? One share of BEAM stock can currently be purchased for approximately $40.42. How much money does Beam Therapeutics make? Beam Therapeutics (NASDAQ:BEAM) has a market capitalization of $2.84 billion and generates $51.84 million in revenue each year. The company earns $-370.64 million in net income (profit) each year or ($3.610010) on an earnings per share basis. How many employees does Beam Therapeutics have? Beam Therapeutics employs 341 workers across the globe. How can I contact Beam Therapeutics? Beam Therapeutics' mailing address is 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139. The official website for Beam Therapeutics is www.beamtx.com. The company can be reached via phone at 857-327-8775 or via email at [email protected]. This page (NASDAQ:BEAM) was last updated on 6/30/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here